Skip to content

Neil McNaughton

12 papers in the library · 133 citations · publishing 2008-2026

Papers

Sort Most recent Most cited

Ketamine Dose and Duration Effects in Internalizing Disorders

The Journal of Clinical Pharmacology September 1, 2026 Neil McNaughton, Ben Beaglehole, Paul Glue

The dose-response profile of racemic ketamine in internalizing disorders is poorly characterized. This was a secondary analysis of outcome responses in patients with treatment-resistant depression, post-traumatic stress disorder, generalized and/or social anxiety, or obsessive-compulsive disorder. For each disorder, they received single intramuscular doses of racemic ketamine (0.5 and 1.0...

Ketamine effects on EEG and their links to therapy differ across treatment-resistant major depression, post-traumatic stress disorder, and obsessive-compulsive disorder

The International Journal of Neuropsychopharmacology July 6, 2026 Shabah M. Shadli, Neda Nasrollahi, Calvin K. Young et al.

BACKGROUND: Neurotic disorders - major depressive disorder (MDD), panic disorder, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and specific phobia - have differing pharmaceutical profiles. But all, even when resistant to conventional treatment (TR), respond quickly to low dose (0.5-1.0 mg/kg I.M.) ketamine....

Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments.

Journal of the Royal Society of New Zealand February 1, 2026 Neil McNaughton, Shabah M. Shadli, Ben Beaglehole et al.

The neurotic disorders (e.g., depression, dysthymia, generalized anxiety disorder, panic disorder, agoraphobia, social anxiety, post-traumatic stress disorder, and obsessive-compulsive disorder) are costly and difficult to treat. Diagnosis is based on symptoms not biological causes. Here, we summarize New Zealand-based work developing EEG biomarkers and novel treatments. Working at the...

Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study

BJPsych Open October 1, 2025 Ben Beaglehole, Paul Glue, Shona Neehoff et al. 5 citations

We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD. Further work is required to establish the optimal dosing regimen and longer-term role of ketamine in treatment of PTSD, but our findings are encouraging given the well-known of treatments in this area.

Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder.

Journal of Psychopharmacology June 5, 2025 Ben Beaglehole, Paul Glue, Shona Neehoff et al. 19 citations

We previously completed a double-blind randomised crossover study assessing intramuscular ketamine for treatment-resistant depression (TR-D), post-traumatic stress disorder (TR-PTSD) and obsessive-compulsive disorder (TR-OCD). Here, we report an extension study to explore the ongoing benefits and tolerability of maintenance oral ketamine. All participants from the original study were eligible...

Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study.

Journal of Psychopharmacology 2025 Ben Beaglehole, Paul Glue, Shona Neehoff et al. 12 citations

Obsessive-Compulsive Disorder (OCD) may respond to ketamine treatment. To examine the responsiveness and tolerability of treatment-refractory OCD to intramuscular (IM) ketamine compared to IM fentanyl. This was a randomised double-blind psychoactive-controlled study with single doses of racemic ketamine 0.5 mg/kg, 1.0 mg/kg or fentanyl 50 µg (psychoactive control). Pre-dosing with 4 mg oral...

DOI: 10.1177/02698811241301215 (opens in new tab) Full text (opens in new tab) Mental health OCD Obsessive-Compulsive Disorder Ketamine therapy Clinical trials +1

Interaction between perineuronal nets and ketamine in antidepressant action

bioRxiv Preprint Server May 30, 2021 Calvin K. Young, Kachina G. Kinley, Neil McNaughton preprint

Depression is highly prevalent, increases suicide risk, and is now the leading cause of disability worldwide. Our ability to treat depression is hampered by the lack of understanding of its biological underpinnings and of the mode of action of effective treatments. We hypothesised that the scaffolding proteins in the medial frontal cortex play a major role in effective antidepressant action. We...

Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study

Journal of Psychopharmacology March 1, 2020 Paul Glue, Shona Neehoff, A. Sabadel et al. 97 citations

Background: We previously reported that ketamine has anxiolytic effects in patients with treatment-resistant generalized anxiety and social anxiety disorders. Aims: The purpose of this study was to replicate our earlier report about ketamine‘s anxiolytic activity, using a more robust study design. Methods: This was a double-blind, psychoactive-controlled ascending dose study in 12 patients with...

Ketamine Effects on EEG during Therapy of Treatment-Resistant Generalized Anxiety and Social Anxiety.

The International Journal of Neuropsychopharmacology August 1, 2018 Shabah Mohammad Shadli, Tame Kawe, Daniel Martin et al.

Ketamine is swiftly effective in a range of neurotic disorders that are resistant to conventional antidepressant and anxiolytic drugs. The neural basis for its therapeutic action is unknown. Here we report the effects of ketamine on the EEG of patients with treatment-resistant generalized anxiety and social anxiety disorders. Twelve patients with refractory DSM-IV generalized anxiety disorder...

Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders.

Journal of Psychopharmacology June 2018 Paul Glue, Shona Neehoff, Natalie J. Medlicott et al.

In this maintenance treatment study, we sought to evaluate the effect on anxiety ratings, safety and tolerability of 3 months of weekly ketamine in 20 patients with treatment-refractory DSM IV generalised anxiety disorder (GAD) and/or social anxiety disorder (SAD), and subsequent assessment of remission post-treatment. This was an uncontrolled open-label study in 20 patients who had been...

DOI: 10.1177/0269881118762073 (opens in new tab) Full text (opens in new tab) Ketamine Generalised anxiety disorder Maintenance treatment Social anxiety disorder

Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.

Journal of Psychopharmacology October 2017 Paul Glue, Natalie J. Medlicott, Sarah Harland et al.

The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder. Due to similarities in brain network activity in depression and anxiety disorders, we hypothesized that ketamine might also be active in other refractory anxiety disorders. We evaluated the efficacy and safety of...

Frontal-midline theta from the perspective of hippocampal "theta".

Progress in Neurobiology November 2008 Damon J Mitchell, Neil McNaughton, Danny Flanagan et al.

Electrical recordings from the surface of the skull have a wide range of rhythmic components. A major task of analysis of this EEG is to determine their source and functional significance. The hippocampal "theta rhythm" has been extensively studied in rats and its rhythmicity has recently been shown to be functionally significant, per se. Here, we use relevant aspects of the hippocampal...